© Reuters. FILE PHOTO: A pharmacist holds a vial of the Moderna coronavirus illness (COVID-19) vaccine in West Haven, Connecticut, U.S., February 17, 2021. REUTERS/Mike Segar
(Reuters) – Moderna (NASDAQ:)’s COVID-19 vaccine could pose a better threat of coronary heart irritation than Pfizer-BioNTech’s in shot some age teams, the U.S. Facilities for Illness Management and Prevention mentioned on Tuesday.
The company, nonetheless, mentioned that the findings on myocarditis and pericarditis, kinds of coronary heart irritation linked with each the mRNA pictures, weren’t constant throughout all the U.S. vaccine security monitoring methods.
